REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Protocols
5

TB-500 dosage timing question

Cameron Chen 8·4 days ago
Looking for input from experienced users on this topic. I have done a lot of reading but wanted to get real-world perspectives from people who have actually tried different approaches. What has worked best for you?

Comments (4)

Jordan Volkov 501·2 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Jordan Murphy 601·about 2 months ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Jordan Johansson 701·about 1 month ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2
Jordan Nakamura 801·20 days ago

Great write-up! This matches my experience almost exactly. The dosing you mentioned is what I settled on too after some experimentation.

2

Sign in to comment.